Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is highlighted as a promising small-cap stock with significant upside potential, particularly following the FDA approval of Orladeyo for pediatric patients with hereditary angioedema [1][2]. Group 1: FDA Approval and Product Details - On December 12, BioCryst Pharmaceuticals announced that the FDA approved its New Drug Application for an oral pellet formulation of ORLADEYO (berotralstat) for pediatric patients aged 2 to <12 years with hereditary angioedema [2]. - ORLADEYO is noted as the first and only targeted oral prophylactic therapy for this age group, which previously had limited treatment options that were burdensome [2]. - The company also reported that a capsule formulation of ORLADEYO was approved in December 2020 for patients aged 12 years and older, and it is now approved in over 45 countries [3]. Group 2: Investment Outlook - H.C. Wainwright raised the price target for BioCryst Pharmaceuticals from $30 to $32 and reaffirmed a Buy rating, citing the approval of Orladeyo as a significant factor for this update [1]. - The company is recognized for its innovative approach in biotechnology, focusing on structure-guided drug design to develop therapies for rare diseases [3].

This article looks at the 14 Best Multibagger Penny Stocks to Buy Right Now.The Russell 2000 Index has hit fresh highs heading into 2026, signaling renewed interest in small companies. The index is already up by more than 13% for the year as market rotation from large-cap stocks gathers pace.The renewed focus on penny and small-cap stocks comes as investors rotate into higher-risk, higher-reward assets. The shift also underscores growing confidence in the broader economy and corporate sector, as they are ex ...

Group 1 - Sonnet BioTherapeutics Holdings, Inc. announced that its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC at a special meeting [1] - The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission [1] Group 2 - Sonnet BioTherapeutics is an oncology-focused biotechnology company that utilizes a proprietary platform known as FHAB (Fully Human Albumin Binding) for developing biologic drugs [2] - The FHAB technology employs a fully human single chain antibody fragment that binds to human serum albumin for targeted transport to tumor and lymphatic tissues, enhancing the safety and efficacy of immune modulating biologic drugs [2] - FHAB serves as a modular construct for various large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines [2]

Core Insights - Rapport Therapeutics is set to present results from its Phase 2a trial of RAP-219 for focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, highlighting new efficacy analyses and treatment effects [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [8]. - The company's lead investigational drug, RAP-219, is designed to selectively target TARPγ8, a receptor associated protein expressed in specific brain regions, potentially offering a differentiated profile compared to traditional neuroscience medications [7][8]. Clinical Trial Details - The Phase 2a trial of RAP-219 will present topline efficacy and safety data, including the drug's effects during the first month of treatment and its consistency in efficacy throughout the treatment period [2][4]. - Additional analyses will cover the impact of baseline disease severity on efficacy outcomes and the effect of RAP-219 on seizure severity [2][6]. Presentation Schedule - The company will host a dedicated Scientific Exhibit Room at the meeting, featuring multiple poster presentations on RAP-219's clinical program [4][5]. - Specific poster sessions are scheduled for December 7 and 8, 2025, detailing various aspects of RAP-219's efficacy and safety [5][6].

Core Viewpoint - Moderna, Inc. has secured a five-year term loan facility of up to $1.5 billion from Ares Management, enhancing its financial flexibility while maintaining a strong balance sheet [1] Group 1: Financing Details - The financing is structured as non-dilutive debt, consisting of three tranches over five years [1] - The initial tranche includes a $600 million term loan funded at closing [1] - A $400 million delayed draw term loan facility (DDTL) is available for multiple draws at Moderna's discretion through November 2027 [1] - An additional $500 million DDTL is also available for multiple draws at Moderna's discretion through November 2028 [1] Group 2: Financial Guidance - The company has reiterated its financial guidance for 2025, as provided during the 3Q25 earnings call [1] - Moderna is targeting cash breakeven by 2028 [1]

Core Insights - Silence Therapeutics (SLN) is positioned as a focused, clinical-stage RNAi drug development company, but its valuation is impacted by historical execution concerns and the general fatigue in the small-cap biotech sector [1] Company Analysis - The company is seen as having high growth potential, particularly in sectors that are expected to experience exponential expansion [1] - There is a strong emphasis on the importance of innovation in generating substantial returns, indicating a forward-looking approach to investment in disruptive technologies [1] Market Context - The current market sentiment reflects a broader exhaustion in the small-cap biotech space, which may affect investor confidence and company valuations [1]

Core Insights - The Baron International Growth Fund gained 6.04% in Q3 2025, slightly underperforming the MSCI ACWI ex USA Index which appreciated 6.89% [3][4] - The performance was influenced by the Federal Reserve's easing cycle and significant investments in AI data center capacity and GPU commitments [4] Top Contributors to Performance - Lynas Rare Earths Limited contributed 1.25% to returns, with shares nearly doubling due to geopolitical tensions highlighting the importance of non-China supply sources [5] - Argenx SE added 0.79%, driven by strong sales of its drug Vyvgart, which exceeded expectations and showed potential for growth in autoimmune conditions [6] - Lundin Mining Corporation contributed 0.66%, benefiting from solid financial results and a tightening copper supply due to competitor production suspension [7] - Taiwan Semiconductor Manufacturing Company Limited and Contemporary Amperex Technology Co., Limited also contributed positively to the Fund's performance [5] Top Detractors from Performance - Constellation Software Inc. detracted 0.70% due to uncertainty around AI's impact on software and the announcement of leadership changes [8] - InPost S.A. contributed a negative return of 0.39% as concerns arose over its largest customer Allegro exploring alternative logistics solutions [9] - ODDITY Tech Ltd. saw a decline of 0.37% despite exceeding expectations, as investors were concerned about the magnitude of the earnings beat and future cost pressures [10]

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its primary drug candidate being sonelokimab (SLK) for treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, which is an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or increased tissue penetration as claimed [4]. Stock Impact - Following the announcement of disappointing Phase 3 VELA program results on September 28, 2025, which indicated SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased MoonLake common stock during the class period to seek lead plaintiff status in the lawsuit, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].

Core Viewpoint - Arvinas, Inc. is advancing its investigational drug ARV-393, a PROTAC designed to degrade the BCL6 protein, which is a significant driver of B-cell lymphomas, and will present preclinical data in December 2025 at the ASH Annual Meeting [1][3]. Group 1: About ARV-393 - ARV-393 targets the BCL6 protein, which plays a crucial role in B-cell lymphoma by repressing cell cycle checkpoints and apoptosis, making it a challenging target for traditional therapies [3]. - The drug is currently in a Phase 1 clinical trial for patients with non-Hodgkin lymphoma, indicating its potential therapeutic application in this area [3]. Group 2: About Arvinas - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize its PROTAC platform to selectively degrade disease-causing proteins [4]. - The company is also developing other investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-806 for mutated cancers, and vepdegestrant for ER+/HER2-breast cancer [4].

Core Insights - MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel, which is a significant step towards increasing production capacity for NexoBrid® by approximately sixfold by the end of 2025 [1][2] Company Overview - MediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair, with its FDA-approved product NexoBrid® indicated for the enzymatic removal of eschar in thermal burns [4] - NexoBrid® is approved for use in over 40 countries, including the United States, European Union, and Japan, and is designed to selectively remove non-viable tissue while preserving viable tissue [3] Manufacturing and Supply Capacity - The newly expanded facility will enable a scalable and reliable global supply of NexoBrid across more than 40 approved markets, contingent upon the completion of regulatory reviews [2] - The operational readiness of the expanded facility is expected by year-end 2025, which will help meet the growing global demand for NexoBrid [2][4]